Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pvs25-IMX313
- Development stage
- Phase 1
- Lead developer
- University of Oxford
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pvs25-IMX313 is a transmission-blocking vaccine (TBV) candidate specifically designed to target *Plasmodium vivax*. It is a recombinant fusion protein comprising the Pvs25 ookinete surface antigen fused to the IMX313 oligomerization domain. IMX313 is a pro-immunogenic, heptameric scaffold derived from the chicken C4-binding protein (C4bp) that facilitates the multivalent display of the antigen, which is intended to improve the induction of high-titer, long-lasting antibody responses compared to monomeric antigens. The vaccine's mechanism involves eliciting antibodies in the human host that, when ingested by an *Anopheles* mosquito during a blood meal, bind to the parasite within the mosquito midgut and inhibit its development from zygote to oocyst. This process effectively halts the transmission of malaria from humans back to mosquitoes. The vaccine is formulated with the Matrix-M1 adjuvant (a saponin-based adjuvant) to further enhance its immunogenicity.
- Other names
- Pvs25-IMX313 vaccinePvs-25-IMX313 vaccinePvs 25-IMX313 vaccinePvs25-IMX313/Matrix-M1
02
Targets
Pvs25 (Plasmodium vivax ookinete surface protein 25)
Beyond the preview
Go deeper on Pvs25-IMX313.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pvs25-IMX313.